NEW YORK--(BUSINESS WIRE)--Allosteric Bioscience, Inc., announced today that Dr. Susan Michaelis has joined its Scientific Advisory Board (SAB). Dr. Michaelis is a leading scientist working on fundamental cell and molecular processes related to human health, disease and longevity and she is a Professor of Cell Biology in the Johns Hopkins University School of Medicine.
Dr. Michaelis is focused on understanding the mechanism of the premature aging genetic disease Progeria; the disease results in premature aging of individuals starting at about one year of age and these children generally don’t survive past their late teens. The disease is a result of a mutation in the human Lamin A gene which is critical for normal cell function. Her work involves Human Genetics, Genomics as well as Cell and Molecular Biology.
“Dr. Michaelis will be a great addition to the Allosteric Bioscience SAB due to her outstanding scientific skills addressing some of the proteins Allosteric Bioscience is targeting for improvement and optimization of the Aging and Longevity process,” said Dr. Arthur P. Bollon, Ph.D., President and Co-Founder of Allosteric Bioscience, Inc.
“Allosteric Bioscience has a unique angle on aging research and aims to improve both lifespan and healthspan,“ said Dr. Susan Michaelis.
Dr. Michaelis will serve on the Scientific Advisory Board as an advisor on complex Aging and Longevity molecular mechanisms. Her insights will complement those of the leading scientists of the company’s team. Participation by Dr. Susan Michaelis (Consultant) as an advisor to Allosteric Bioscience, Inc. (Company) does not constitute or imply endorsement of Allosteric Bioscience, Inc. (Company) by Johns Hopkins University.
Allosteric Bioscience, Inc. is a biopharmaceutical company focused on using the Quantum Computer and advanced Artificial Intelligence integrated with biomedical sciences such as Genetics, Genomics, Cell Biology and others, for improving and optimizing the Aging and Longevity Process. The company is creating and analyzing chemical leads which have the potential for treating the premature aging disease Progeria and for optimizing the Normal Aging and Longevity process.
Forward Looking Statement
The information contained in this communication is for information purposes only and may contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, but not limited to, statements as to future operating results and plans that involve risks and uncertainties. We use words such as “expects”, “anticipates”, “believes”, “estimates”, the negative of these terms and similar expressions to identify forward looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by those projected in the forward-looking statements for any reason. This is neither a solicitation of investment nor an offer to sell and/or buy securities. References herein to “the Company,” “we”, “our,” “us” and similar words or phrases are references to Allosteric Bioscience and/or its subsidiaries, unless the context otherwise requires.